Latest news with #PlasmodiumFalciparum
Time Business News
6 days ago
- Health
- Time Business News
Innovative Frontiers in Artemisinin Combination Therapy
To increase efficacy and reduce the risk of drug resistance, artemisinin combination therapy (ACT) treats malaria by mixing an artemisinin-based molecule with one or more fellow drugs. Artemisinin Combination Therapy (ACT) has expanded considerably due to high malaria burden in Southeast Asia and sub-Sahara Africa in the market due to its effectiveness against high malaria burden and drug-resistant Plasmodium Falciparum. Global health initiatives such as WHO guidelines and funding support have improved access and strength. The ongoing drug progress has also increased treatment efficacy and adherence to the patient, collectively increased market growth. Key Growth Drivers and Opportunities Urgent Demand for More Effective Malaria Treatments: A major trend that runs the future of the market is required for more effective malaria remedies between persistent cases and increasing drug resistance. It is promoting innovation in ACT formulations to develop rapid acting, long lasting, and more patient -friendly options. With increased government and international health funding, this progress is improving access and distribution in malaria-sustainable regions, the situation serves as a central solution in the global fight against malaria and promotes strong market development. Challenges Artemisinin combination therapy (ACT) faces boundaries due to the emergence of artemisinin-resistant malaria strains in the market, especially in parts of Southeast Asia. Additionally, inconsistent supply chains, high dependence on donor funding, and limited healthcare infrastructure in some spatial regions obstruct wide access. The need for constant innovation to be ahead of regulator challenges and resistance also leads to the ongoing obstacles for market stability and development. Innovation and Expansion Breakthrough A Treatment for Malaria Without Artemisinin Gives Children Hope In November 2024, Positive findings from KALUMI, a Phase 2 study of a new, non-artemisinin malaria medication combination being developed with Novartis and MMV, have been announced by the West African Network for Clinical Trials of Antimalarial Drugs (WANECAM2) consortium. Given that partial resistance to artemisinin derivatives throughout Africa jeopardizes efforts to eradicate the illness, this is a significant advancement in the fight against malaria. The effectiveness and safety of a combination of lumefantrine, reformulated for once-daily dosage, and ganaplacide, a new drug, were assessed in the KALUMI trial. This novel combination was tested against artemether-lumefantrine, the most popular artemisinin-based combination therapy (ACT) for treating uncomplicated malaria in Africa. Fosun Pharma Acquires USD 3.5M to Promote the Development of Malaria Treatments In December 2023, The Japanese Global Health Innovative Technology (GHIT) Fund has awarded Y500m (USD 3.3m) to China-based Fosun Pharma to further the development of a triple artemisinin combination medication for the treatment of malaria. Artemether, lumefantrine, and amodiaquine are the three antimalarial medications that make up the triple artemisinin combination medication, which comes in a fixed dosage format. The money used to support the Phase III research that looks into the combo treatment. Fosun, the Japanese investment firm Marubini, the Thailand-based research partnership of the universities Mahidol-Oxford Tropical Medicine Research Unit (MORU), and the product development partnership Medicines for Malaria Venture (MMV) will all work together to undertake the III trial. Novartis Provides One Billion Antimalarial Treatment Courses Globally In May 2021, Novartis declared that since 1999, it has provided one billion antimalarial therapy sessions. Over 90% of this artemisinin-based combination treatment (ACT) was given to malaria-endemic nations worldwide at no profit. The most lethal kind of malaria, P. falciparum, which accounts for more than 99% of cases in Africa and half of those in Asia, is treated with ACTs as the standard of care2. ACTs have revolutionized the treatment of malaria since the turn of the century and helped to significantly lower the number of malaria-related fatalities. Inventive Sparks, Expanding Markets Among the leading companies for artemisinin combination therapy are Novartis AG, Cipla, Bliss GVS, and KPC Pharmaceuticals, Inc. The artemisinin combination therapy (ACT) firm is focusing on developing more effective and affordable formulations, such as drug-resistant and kid-safe variants, in order to enhance treatment outcomes and accessibility. Working with governments and international health organizations is another important strategy to expand distribution in malaria-endemic areas. To ensure consistent availability, local production and supply linkages are also reinforced. These programs support global efforts to eradicate malaria, combat medication resistance, and improve patient compliance. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Hans India
25-04-2025
- Health
- Hans India
Cambodia on verge of achieving malaria-free goal: PM Hun
Cambodia is making great progress towards achieving its malaria-free target by the end of 2025, Prime Minister Hun Manet said. In a message to mark the National Malaria Day on Friday, he said the Southeast Asian country reported only 355 malaria cases in 2024, a significant drop of 75 per cent compared to 2023. The prime minister added that the kingdom had reported zero deaths from the disease since 2018 and no local Plasmodium Falciparum cases since 2024. "Cambodia is on the verge of achieving a malaria-free goal by the end of 2025," Hun Manet said, urging all stakeholders to continue to support the country to achieve the target. Huy Rekol, director of the National Center for Parasitology, Entomology and Malaria Control, said malaria diagnostic tests and treatments have been highly effective in Cambodia, with Artesunate/Mefloquine, or ASMQ, being 100 per cent safe and efficacious against malaria, Xinhua news agency reported. "This progress has put Cambodia in the category of successful countries in eliminating malaria," he told Xinhua. Malaria is a mosquito-borne infectious disease that is typically found in forest and mountainous provinces, especially during rainy seasons. To avoid being bitten by malaria-carrying mosquitoes, Rekol advises people living in malaria-risk areas to sleep under insecticide-treated mosquito nets at all times. Symptoms can be mild or life-threatening. Mild symptoms are fever, chills and headache. Severe symptoms include fatigue, confusion, seizures, and difficulty breathing. Infants, children under 5 years, pregnant women and girls, travellers and people with HIV or AIDS are at higher risk of severe infection. Malaria can be prevented by avoiding mosquito bites and with medicines. Treatments can stop mild cases from getting worse. Malaria mostly spreads to people through the bites of some infected female Anopheles mosquitoes. Blood transfusion and contaminated needles may also transmit malaria. The first symptoms may be mild, similar to many febrile illnesses, and difficulty to recognise as malaria. Left untreated, P. falciparum malaria can progress to severe illness and death within 24 hours.
